Array biopharma inc (ARRY)
CashFlow / Yearly
Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10
Cash flows from operating activities
Net Income (Loss) Attributable to Parent

-147,346

-116,818

-92,840

9,369

-85,257

-61,942

-23,581

-56,324

-77,631

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

2,236

2,068

1,529

3,702

4,506

4,350

5,076

7,616

6,338

Non-cash interest expense

6,252

7,223

6,375

5,799

5,258

4,476

4,643

6,377

6,737

Share-based compensation expense

19,107

9,965

7,283

7,809

4,331

3,449

2,351

3,328

5,372

Impairment of marketable securities

-

-

-

-

-

-

-

-

217

Loss on extinguishment and conversion of notes

-6,457

0

0

-

-

-11,197

-942

-6,340

-

Extinguishment of co-development liability, net

-

-

-

21,610

0

0

-

-

-

Realized gain or loss on investments, net

0

529

0

16,255

0

0

-

-

-

Gain on sale of CMC, net

-

-

-

1,641

0

0

-

-

-

Impairment loss related to cost method investment

0

1,500

0

0

-

-

-

-

-

Financing fees on notes payable

0

240

0

0

-

-

-

-

-

Change in fair value of notes payable

3,299

2,600

0

0

-

-

-

-

-

Payment of employee bonus with stock

-

-

-

-

-

2,857

1,969

3,982

2,412

Non-cash license revenue

-

-

-

-

4,500

0

0

-

-

Changes in operating assets and liabilities:
Realized gains on auction rate securities, net

-

-

-

-

-

-

-

1,891

1,444

Accounts receivable

805

-8,023

32,995

7,592

-4,166

8,520

-1,157

487

-

Prepaid expenses and other assets

3,067

-6,179

4,352

1,260

1,961

746

-1,044

632

658

Accounts payable and other accrued expenses

5,716

-1,004

3,931

-1,113

1,866

-1,324

1,084

-1,173

-1,064

Accrued outsourcing costs

465

12,248

1,738

7,362

4,464

182

146

341

148

Accrued compensation and benefits

5,390

1,539

1,126

-702

-1,272

1,951

1,099

-3,582

2,165

Co-development liability

-

-

-

12,169

5,165

1,812

5,581

3,597

-

Deferred rent

-33

1,564

175

-3,236

-3,645

-3,489

-3,332

-3,180

3,034

Deferred revenue

-17,661

25,664

37,831

1,584

-4,807

-41,214

-31,613

-30,471

78,078

Other non-current liabilities

207

184

109

-178

4

-106

-112

197

-

Other liabilities and accrued expenses

-

-

-

-

-

-

-

-

250

Net cash used in operating activities

-119,783

-39,354

-70,090

-5,793

-71,682

-87,067

-33,546

-65,962

17,886

Cash flows from investing activities
Purchases of property and equipment

1,232

3,520

3,159

2,507

2,614

2,340

1,437

1,901

1,253

Proceeds from investment

0

529

0

0

-

-

-

-

-

Proceeds from sale of CMC

-

-

-

3,750

0

0

-

-

-

Proceeds from investment

442,602

387,554

139,150

202,908

95,602

110,723

51,339

53,427

79,375

Purchases of marketable securities

252,797

332,429

208,336

143,616

100,698

96,701

34,055

129,423

11,237

Net cash used in investing activities

-191,037

-58,116

66,027

-58,049

2,482

-16,362

-18,721

74,095

-69,391

Net proceeds from the issuance of common stock

-

-

-

-

75,000

75,555

67,145

6,060

11,596

Payments of Stock Issuance Costs

-

-

-

-

1,552

4,659

3,997

281

-

Proceeds from notes payable at fair value

0

10,000

0

0

-

132,250

0

0

-

Net proceeds from employee stock purchases and options exercised

20,775

2,344

2,032

4,398

3,693

2,120

1,169

1,491

1,176

Payment of offering costs

-

-

-

-

-

-

-

-

623

Payment of Comerica term loan

0

14,550

0

0

-

92,712

4,350

150

-

Proceeds from the modification of long-term debt, net

0

15,000

0

0

-

-

-

-

40,000

Payment for debt issuance costs

-

-

-

0

86

4,188

0

0

1,000

Warrants exercised for cash

0

0

46

0

0

-

-

-

-

Net cash provided by financing activities

299,635

166,805

4,970

50,942

77,055

108,366

59,967

7,120

51,149

Net increase in cash and cash equivalents

-11,185

69,335

907

-12,900

7,855

4,937

7,700

15,253

-356

Supplemental disclosure of cash flow information
Cash paid for interest

4,026

4,386

4,466

4,450

4,349

6,564

7,008

9,105

8,540

Cash paid for income taxes

2,300

0

0

-

-

-

-

-

-

Change in unrealized gain (loss) on marketable securities

-385

-83

2

3

4

-1

-

-

-